Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00880191 · ClinicalTrials.gov registry record · Phase 3
Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 430
- Enrollment target
NCT00880191 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 430 participants.
The verdict
NCT00880191, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 430 participants
- Enrollment target
Study Summary
RATIONALE: Gabapentin may prevent or reduce delayed nausea and vomiting caused by chemotherapy. It is not yet known whether gabapentin is more effective than a placebo in preventing nausea and vomiting. PURPOSE: This randomized phase III trial is studying the side effects of gabapentin and to see how well it works compared with a placebo in preventing nausea and vomiting in patients receiving chemotherapy.
Interventions
- OTHER placebo
- DRUG dexamethasone
- DRUG gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2009-04 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00880191
The ClinicalTrials.gov registry entry for NCT00880191 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00880191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00880191 about?
NCT00880191 is a clinical study titled "Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy". RATIONALE: Gabapentin may prevent or reduce delayed nausea and vomiting caused by chemotherapy. It is not yet known whether gabapentin is more effective than a placebo in preventing nausea and vomiting. PURPOSE: This randomized phase III trial is studying the side effects of gabapentin and to see h...
What is the current status of trial NCT00880191?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 2009-04. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00880191?
The interventions under investigation include: placebo (OTHER), dexamethasone (DRUG), gabapentin (DRUG).
Who is sponsoring clinical trial NCT00880191?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.